论文部分内容阅读
目的 评价口服依托泊苷治疗转移性乳腺癌的疗效和不良反应.方法 回顾性分析88例接受口服依托泊苷治疗的转移性乳腺癌患者资料.口服依托泊苷50 mg/d,dl～20,每28天为一周期.结果 共纳入88例乳腺癌患者,83.0％(73/88)为三线以上治疗,78.4％(69/88)既往用蒽环类、紫杉类药物及卡培他滨治疗过.88例患者采用口服依托泊苷方案中位化疗5周期,均可评价疗效,其中部分缓解(PR)7例(8.0％),疾病稳定(SD) 50例(56.8％),疾病进展(PD) 31例(35.2％),无完全缓解(CR)患者.客观缓解率(CR+PR)为8.0％,临床获益率(CR+PR+SD≥6.0月)为44.3％.整体中位无进展生存期(PFS)为5.0月(95％CI:3.8～6.2月),中位生存期(OS)为17.0月(95％CI:11.3～22.7月).主要不良反应为1～2级恶心18例(20.5％),1～2级中性粒细胞减少19例(21.6％),3级中性粒细胞减少3例(3.4％).结论 口服依托泊苷治疗难治性转移性乳腺癌耐受性好、有一定疗效.“,”Objective To determine the efficacy and safety of oral etoposide on metastatic breast cancer.Methods In this retrospective trial,88 metastatic breast cancer(MBC) patients received oral etoposide 50 mg/d on days 1-20 every 28 days.Results A total of 88 patients with MBC were enrolled,83.0％(73/88) of the patients received multiple line(≥3 lines) chemotherapy,and 78.4％(69/88) of the patients had been pretreated with anthracycline,taxane,and capecitabine.All patients received median five cycles of oral etoposide therapy and all were evaluable for response,7(8.0％) patients achieved partial response (PR),50(56.8％) patients had stable disease(SD),31(35.2％) had progressive disease(PD) and no one achieved complete response(CR).The objective response rate(ORR,CR+PR) was 8.0％ and the clinical benefit rate (CBR,CR+PR+SD≥6.0 months) was 44.3％.Median progression free survival(PFS) was 5.0 months(95％CI:3.8-6.2 months).Median overall survival(OS) was 17.0 months(95％CI:11.3-22.7 months).The main toxicities were grade 1-2 nausea(20.5％),grade 1-2 neutropenia(21.6％),grade 3 neutropenia(3.4％).Conclusion Oral etoposide could be an option with efficacy and safety for heavily pretreated metastatic breast cancer.